Thyroid Dysfunction and Infertility: A Complete Guide to Diagnosis and Treatment

Thyroid dysfunction and infertility describes the well-established clinical relationship in which abnormal thyroid hormone levels, whether too low (hypothyroidism) or too high (hyperthyroidism), interfere with ovulation, menstrual regularity, implantation, and the ability to sustain a pregnancy. The thyroid gland produces hormones that regulate virtually every metabolic process in the body, including the hormonal cascades that govern the female reproductive cycle. When thyroid function is impaired, fertility is often compromised as a direct consequence.

The connection matters because thyroid disorders are common in women of reproductive age and are frequently underdiagnosed. According to a review published on NIH PubMed Central, subclinical hypothyroidism affects 5–7% of women aged 20–45, overt hypothyroidism affects 2–4.5%, and thyroid autoimmunity is present in 5–10% of this group. Many of these women present first to a fertility clinic rather than an endocrinologist, making thyroid screening an essential part of any infertility workup.

The main forms of thyroid dysfunction and infertility-related conditions are subclinical hypothyroidism, overt hypothyroidism, hyperthyroidism, and thyroid autoimmunity. Subclinical hypothyroidism is defined by a raised TSH (thyroid-stimulating hormone) with normal free thyroid hormone levels and is the most common form seen in infertile women. Overt hypothyroidism involves both a raised TSH and low free T4, producing more pronounced symptoms. Hyperthyroidism, excess thyroid hormone, is less common but also disrupts reproductive function.

Thyroid autoimmunity refers to the presence of antibodies, most commonly anti-thyroid peroxidase antibodies (TPOAb), that attack thyroid tissue. A woman can have normal TSH levels and still carry these antibodies, which independently raise the risk of miscarriage and poor ART outcomes. According to NIH PubMed Central, thyroid autoimmunity is more prevalent among infertile women than in the general population, making antibody testing a critical part of the fertility assessment.

• Condition: Subclinical hypothyroidism · TSH Level: Raised (>4.0 mIU/L) · Free T4: Normal · Prevalence in Women 20–45: 5–7%
• Condition: Overt hypothyroidism · TSH Level: Raised (>4.0 mIU/L) · Free T4: Low · Prevalence in Women 20–45: 2–4.5%
• Condition: Hyperthyroidism · TSH Level: Suppressed (<0.4 mIU/L) · Free T4: High · Prevalence in Women 20–45: 0.5–1%
• Condition: Thyroid autoimmunity (euthyroid) · TSH Level: Normal · Free T4: Normal · Prevalence in Women 20–45: 5–10%

Thyroid hormones act directly on ovarian granulosa cells, the cells that surround and nourish developing eggs, enhancing their proliferation and preventing premature cell death. They also regulate endometrial receptivity, the quality of the uterine lining that an embryo must implant into. When thyroid hormone levels fall, the downstream effects include altered gonadotropin (FSH and LH) release, decreased sex hormone-binding globulin, elevated prolactin, and ovulatory dysfunction, all of which reduce the likelihood of natural conception.

Research published on NIH PubMed Central confirms that thyroid hormones interact with reproductive hormones at multiple levels, from the hypothalamus down to the ovary itself. This means that even a modest reduction in thyroid function, one that might not cause fatigue or weight gain, can quietly undermine a woman's fertility. For women exploring ovarian reserve testing or investigating unexplained infertility, thyroid function is one of the first variables the team at Jananam will assess.

Thyroid dysfunction and infertility are often first signalled by changes in the menstrual cycle. Hypothyroidism is associated with menorrhagia (heavy periods), oligomenorrhea (infrequent periods), and in severe cases amenorrhea (absent periods). According to NIH PubMed Central, 25–60% of women with overt hypothyroidism report menstrual irregularities, compared with only around 10% of women with normal thyroid function.

These disruptions occur because thyroid hormones influence the production and clearance of oestrogen and progesterone. Low thyroid hormone levels reduce sex hormone-binding globulin, allowing more free oestrogen to circulate, which can cause heavy or prolonged bleeding. Simultaneously, impaired ovulation means progesterone levels after mid-cycle are insufficient to regulate the cycle properly. Women presenting with endometriosis or PCOS alongside menstrual irregularities should be screened for thyroid dysfunction, as these conditions can coexist and compound one another.

The hypothalamic–pituitary–thyroid (HPT) axis is the hormonal feedback loop that controls thyroid hormone production. When thyroid hormone levels drop, the hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary to produce more TSH. The problem for fertility is that elevated TRH also stimulates the pituitary to secrete prolactin, a hormone that, at high levels, suppresses the pulsatile release of GnRH (gonadotropin-releasing hormone) needed to trigger ovulation.

High prolactin disrupts LH and FSH secretion, leading to anovulation and infertility. An Indian cross-sectional study of 205 women attributes the hyperprolactinemia seen in hypothyroidism to increased TRH production. This is why a woman with hypothyroidism may also be found to have hyperprolactinemia, elevated prolactin, on blood testing, even without a pituitary tumour. In a study of 1,003 newly diagnosed hypothyroid patients, about 8% had raised prolactin, and prolactin fell with levothyroxine in those not taking interfering drugs, although menstrual irregularities persisted (Raber et al., 2003).

Thyroid autoimmunity (the presence of anti-thyroid antibodies, particularly TPOAb) raises the risk of infertility and pregnancy loss even when TSH and free T4 are within the normal range. According to a review in Clinical and Experimental Reproductive Medicine, thyroid autoimmunity is associated with an odds ratio of 1.5 for unexplained infertility, an odds ratio of 3.73 for miscarriage, and an odds ratio of 2.3 for recurrent miscarriage. These are clinically significant risks that justify routine antibody testing in any woman presenting with fertility difficulties.

The mechanisms are not fully understood, but thyroid antibodies may reflect a broader immune dysregulation that also affects implantation and early placental development. Women with a history of recurrent miscarriage should specifically request TPOAb testing if it has not already been performed. The team at Jananam includes thyroid autoimmunity assessment as part of a thorough fertility workup, recognising that a normal TSH result alone does not rule out thyroid-related reproductive risk.

Thyroid dysfunction and infertility interact directly with assisted reproductive technology (ART) outcomes. Elevated TSH above 4.0 mIU/L has been associated with impaired fertilisation rates and poorer embryo quality in IVF cycles. According to NIH PubMed Central, meta-analyses mainly in women with TSH above 4.0 mIU/L found that levothyroxine before ART increased live birth rates, making pre-treatment thyroid optimisation a standard step before any cycle begins.

For euthyroid women, those with normal TSH but positive thyroid antibodies, the evidence on whether levothyroxine improves live birth rates is less clear-cut; the same review notes that routine levothyroxine in this group does not systematically increase live birth rates, though individual clinical judgement applies. Women planning IVF or ICSI at Jananam will have their thyroid status reviewed and optimised before stimulation begins, because even subtle hormonal imbalances can affect egg quality and embryo development in the clinic's Certified Cleanroom Lab environment.

Hyperprolactinemia means abnormally high levels of prolactin in the blood. In the context of thyroid dysfunction and infertility, it arises when hypothyroidism causes TRH to rise, which in turn stimulates excess prolactin secretion from the pituitary gland. Elevated prolactin then suppresses the pulsatile GnRH secretion that drives the monthly hormonal cycle, resulting in anovulation, the absence of ovulation, and infertility.

In a study of 1,003 newly diagnosed hypothyroid patients (Raber et al., 2003), prolactin fell with levothyroxine in those not taking interfering drugs such as antipsychotics. This is an important clinical point: a woman diagnosed with hyperprolactinemia should always have her thyroid function tested before being started on dopamine agonist medications such as cabergoline, because if the prolactin elevation is secondary to hypothyroidism, treating the thyroid is the correct first step. Your consultant at Jananam will sequence these investigations carefully to avoid unnecessary medication.

Diagnosis of thyroid dysfunction in the context of infertility begins with a serum TSH measurement, which is the most sensitive single test for thyroid function. If TSH is abnormal, free T4 and free T3 are measured to distinguish subclinical from overt disease. Thyroid autoantibody testing, specifically anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibodies (TgAb), should be performed alongside TSH, because autoimmunity can be present even when TSH is normal.

According to NIH PubMed Central, guidelines recommend screening all women seeking infertility evaluation for serum TSH and TPOAb before ART. This is not a specialist investigation. It is a standard blood panel that should be part of every initial fertility workup. Women who have already had a basic fertility assessment elsewhere but whose thyroid antibodies were not checked should raise this with their consultant, as the omission can leave a significant risk factor unaddressed.

• Serum TSH: the primary screening test; a result above 4.0 mIU/L warrants further investigation
• Free T4 and free T3: measured when TSH is abnormal to classify the degree of dysfunction
• Anti-TPO antibodies (TPOAb): detect thyroid autoimmunity even when TSH is normal
• Anti-thyroglobulin antibodies (TgAb): a secondary autoimmunity marker, often tested alongside TPOAb
• Prolactin: measured when hypothyroidism is suspected, to identify secondary hyperprolactinemia
• Thyroid ultrasound: used when autoimmunity or structural abnormality is suspected on clinical examination

Levothyroxine, a synthetic form of the thyroid hormone T4, is the treatment of choice for hypothyroidism in women with infertility. For overt hypothyroidism, treatment is always indicated and should be started promptly, with the dose titrated to bring TSH below 2.5 mIU/L before conception or ART. According to NIH PubMed Central, treatment of subclinical hypothyroidism is recommended when TSH exceeds 4.0 mIU/L, and should be considered on a case-by-case basis when TSH is between 2.5 and 4.0 mIU/L in women who also have positive thyroid antibodies.

According to American Thyroid Association guidance, levothyroxine dose requirements rise during pregnancy, so women who conceive after levothyroxine treatment need close monitoring throughout the first trimester. For women with thyroid autoimmunity but normal TSH, the decision to treat is more nuanced and should be guided by the full clinical picture, including antibody titre, reproductive history, and planned treatment pathway. Women preparing for IVF or donor egg IVF will have their levothyroxine dose reviewed and adjusted before the stimulation protocol begins.

• TSH Range: <2.5 mIU/L · Antibody Status: Negative · Recommended Action: No treatment; recheck if symptoms develop
• TSH Range: 2.5–4.0 mIU/L · Antibody Status: Positive (TPOAb) · Recommended Action: Consider levothyroxine on case-by-case basis
• TSH Range: 2.5–4.0 mIU/L · Antibody Status: Negative · Recommended Action: Monitor; treat if TSH rises or symptoms appear
• TSH Range: >4.0 mIU/L · Antibody Status: Any · Recommended Action: Levothyroxine treatment recommended before ART
• TSH Range: Overt hypothyroidism · Antibody Status: Any · Recommended Action: Levothyroxine; titrate to TSH <2.5 mIU/L before conception

Thyroid dysfunction and infertility carry particular significance in the Indian context. A 2024 meta-analysis of 20 Indian studies found a pooled hypothyroidism prevalence of 28% (95% CI 20–36%) among women with infertility. This makes routine thyroid screening during infertility workup not merely advisable but essential for women in Chennai and across Tamil Nadu.

Jananam Fertility Centre in Neelankarai, Chennai, is a single-speciality fertility clinic whose consultants bring over two decades of combined experience in reproductive medicine. The clinic's Certified Cleanroom Lab is designed to maintain optimal conditions for embryo culture, which is particularly relevant for women with low ovarian reserve or poor egg quality, conditions that can be worsened by undertreated thyroid dysfunction. By integrating thyroid assessment into every initial consultation, the team at Jananam ensures that a correctable hormonal imbalance is never the reason a fertility treatment cycle falls short of its potential.

Thyroid dysfunction and infertility are inseparable topics in modern reproductive medicine. A holistic fertility assessment must include thyroid function testing and autoantibody screening, because both overt and subclinical thyroid disease, as well as euthyroid autoimmunity, can silently undermine natural conception and ART outcomes. According to NIH PubMed Central, timely screening, accurate diagnosis, and individualised levothyroxine therapy are necessary to optimise fertility care for affected women.

The good news is that thyroid-related infertility is among the most treatable causes of difficulty conceiving. A simple blood test, a correctly dosed daily tablet, and regular monitoring can transform the hormonal environment for conception. Women who have been trying to conceive for more than 12 months, or six months if over 35, without a clear explanation should ensure their thyroid panel, including antibodies, has been fully evaluated. If you are also exploring options such as IUI or pre-implantation genetic testing, your thyroid status will influence the timing and protocol of those treatments.